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In hematological malignancies, various studies on microRNA (miRNA) profiling have highlighted specific miRNA signatures associated with several clinical conditions, such as disease subtypes, drug responses, and clinical outcomes in leukemia and B cell lymphomas, in parallel with the mRNA profiling study. 1, 2 On the other hand, the characterization of these disease-related miRNA signatures is often compromised by the poor overlapping results of multiple independent studies, even if they focused on the same disease. 3, 4 This problem may be partly explained by a poor overlap among differentially expressed miRNAs identified by multiple miRNA microarray platforms. 4 One promising approach is the paired profiling of mRNAs and miRNAs, and integrated analysis of both to extract disease-related features. Although the pairing of miRNAs and target mRNAs can be inferred from anticorrelation between miRNAs and mRNAs, the generally weak impacts of miRNAs on mRNA expression levels still make this approach difficult.
To this end, we have recently developed GSEA-FAME analysis (GFA) through combining GSEA and FAME to consider weak mRNA changes and the variability of the strength of correlations between an miRNA and its target genes. 5 GFA utilizes mRNA expression profiling to predict alterations in miRNA activities through rank-based enrichment analysis and evaluation of weighted miRNA-mRNA interactions ( Figure 1a) . 5 We demonstrated that GFA is useful for the assessment of widespread correlations between miRNA expression levels and miRNA activity status in diffuse large B cell lymphoma, and that GFA-based inference of miRNA activity improves the extraction of prognostic miRNAs by miRNA profiling in TCGA glioblastoma data set. 5 In this report, we applied this analysis to the gene expression profiling of peripheral T cell lymphomas (PTCL), in which the roles of miRNAs have not been well investigated, and made a prediction map of differential miRNA activities.
Recent miRNA profiling in anaplastic large cell lymphoma (ALCL) showed dysregulated miRNA profiles, including miR-17-92 cluster, miR-106a and miR-155, between anaplastic lymphoma kinase (ALK) þ and ALK À ALCLs. 6 In addition, we and another group reported miR-135b upregulation and miR-29a MRPS25  MYEF2  NPAT  PPP2R5C  PTPN1  RAPGEF6  RNF43  SLC9A9  SNTB2  WIPF1  ZDHHC23  Relative RNA expression   ABAT  ANKRD55  ATP8A1  CRAMP1L  GATA3  MRPS25  MYEF2  NPAT  PIK3CD  PPP2R5C  PTPN1  RAPGEF6  RNF43  SLC9A9  SNTB2  TMEM97  TRPM7  VPS37C  WIPF1 14 downregulation in ALK þ ALCL, respectively. 7, 8 We used the results of comprehensive gene expression profiling on 144 PTCL patients, including AITL, ALK þ ALCL, ALK À ALCL, adult T cell leukemia/ lymphoma (ATLL) and PTCL not-otherwise-specified (PTCL-NOS). 9 We performed GFA between ALK þ ALCL and ALK À ALCL, and between ALK þ ALCL and all PTCL cases so that GFA could be applied for more than two groups. GFA results successfully predicted high activity of miR-106 and miR-135 and low activity of miR-29 in ALK þ ALCL both in comparison with ALK À ALCL and with all cases (Figure 1b) . In miR-17-92 cluster, miR-19 was predicted to be active.
Recently published miRNA and mRNA profiling in the primary clinical samples of adult T cell leukemia (ATL) highlighted the loss of miR-31 in ATL. 10 GFA applied to this data set consistently showed low miR-31 activity in ATL (Figure 1c) . GFA results also highlighted altered activities of several miRNAs such as miR-125 (low), miR-146 (low) and miR-451 (high), which matched the results of miRNA expression profiling in this data set.
As summarized in Figure 1d , GFA for five PTCL subtypes showed the characteristic patterns of different miRNA activities in distinct lymphoma subtypes. For example, miR-10, -217, -300, -382, -495 and -503 were predicted to be active in AITL (Figure 1d, Arrows) . Conversely, miR-27, -124, -138 and -214 were predicted to be underactive in AITL (Figure 1d , Arrows). GFA showed high activity of miR-135 specifically in ALK þ ALCL, and low activity of miR-125 in ATLL (Figure 1d In PTCL-NOS, several miRNAs such as miR-326 and -134 were predicted to be active, and other miRNAs including miR-7 and -208 were predicted to be underactive (Figure 1d , Asterisks). It has been recently shown that the most upregulated (miR-326, -663b and -711) and downregulated (miR-203 and -205) miRNAs in cutaneous T cell lymphoma distinguish cutaneous T cell lymphoma and PTCL-NOS from benign skin diseases. 11 Among these miRNAs, GFA predicted high activity of miR-326 with a Po0.05 threshold, and low activity of miR-205 with a Po0.1 threshold. This implies that these miRNAs may also be useful for the classification of PTCL-NOS and other lymphoma subtypes, in addition to the separation of PTCL-NOS from benign diseases. These results indicate a good correlation between the alteration in miRNA expression levels directly measured in the literature and changes in miRNA activities inferred from independent published gene expression profiling, suggesting that GFA can predict biologically relevant changes in miRNA activities from mRNA profiling. As global miRNA profiling has not been reported in PTCL, this prediction should be assessed further in future investigations. Differences in tumor content in clinical samples, especially low content in AITL and PTCL-NOS, should be also considered for interpretation.
We next investigated whether mRNA profiling can be utilized for reverse identification of disease-related miRNAs and target identification of disease-related miRNAs. We investigated the expression levels of GFA-supported miRNAs in ALK þ ALCL. As shown in Figure 2a , high expression of miR-183, -18a and -19a was confirmed in three ALCL cell lines harboring NPM-ALK fusion; Karpas 299, SUDHL-1 and SUP-M2 cells, relative to normal T cells. In addition to miR-29a, downregulation of miR-24, -185 and -491 was also observed. Furthermore, upregulation of miR-183, -18a and -19a was confirmed in human primary ALK þ ALCL samples, relative to reactive lymph node and ALK À ALCL samples (Supplementary Figure S1) . Interestingly, we observed no significant changes in miR199a and miR-181a in the cell lines, but these miRNAs were upregulated in clinical samples (Figure 2a and Supplementary Figure S1 ). Considering that GFA is based on the expression profiling of clinical samples, the upregulation of miR-199a and miR-181a may be attributable to the in vivo reaction in ALCL.
GFA generates a list of probable target genes for each miRNA for further convenient experimental validation of miRNA-mRNA interactions. Consistent with our report, 8 GFA revealed that high miR-135b activity seems to leave its footprint on clinical ALCL transcriptome. Among the leading-edge gene subset of potential miR-135 target genes that were downregulated in ALK þ ALCL, the top 20 downregulated genes (referred to as 'ALCL-miR-135 target signature') included several genes such as GATA3, PPP2R5C and RAPGEF6 (Figure 2b ). Our previous report showed that GATA3 is a direct target of miR-135b in ALCL. We observed that a large proportion of the 'ALCL-miR-135 target signature' (ATP8A1, MRPS25, MYEF2, NPAT, PPP2R5C, PTPN1, RAPGEF6, RNF43, SLC9A9, SNTB2, WIPF1 and ZDHHC23) was indeed upregulated by miR-135b inhibition in Karpas 299 ALCL cells (Figure 2c) , suggesting the direct contribution of miR-135b to the downregulation of the 'ALCL-miR-135 target signature' in ALCL. We defined a deregulation index for target gene sets by averaging normalized gene expression values and investigated the association between the 'ALCL-miR-135 target signature', which potentially reflects miR-135b activity, and interleukin-17-producing immunophenotype rendered by miR-135b overexpression in ALCL. 8 The deregulation index values of the 'ALCL-miR-135 target signature' and Th17-related genes were clearly low and high in ALK þ ALCL, respectively (Supplementary Figure S2a) , and these two values showed a negative correlation (Supplementary Figure S2b) . Comparable results were confirmed in another data set for T cell lymphoma (Supplementary Figure S2c) . 12 Similar approach also suggested the potential interaction between miR-125 with low activity in ATLL and several known targets, including IRF4, IKZF4, KLF13, ETS1, ARID3B and MCL1 (Supplementary Figure S3) .
Although molecular functions are largely unknown in most 'ALCL-miR-135 target signature' genes, we focused on PPP2R5C, which encodes protein phosphatase 2A (PP2A) regulatory subunit B56g, as PP2A B56g mediates the DNA-damage-induced dephosphorylation and stabilization of p53, and thus exerts a tumor-suppressor function. 13 Exogenous miR-135b suppressed the translational efficiency of PPP2R5C 3 0 -untranslated region depending on the target site (Figures 2d and e) . Knockdown of miR-135b by TuD RNA increased the protein expression levels of PPP2R5C in ALCL cells (Figure 2f ), indicating PPP2R5C as an endogenous miR-135b target. Consistent with the positive effect of PPP2R5C on p53, miR-135b inhibition enhanced p53 accumulation by the DNA damaging agent AraC in p53-wild-type SUP-M2 cells (Figure 2g) . Therefore, NPM-ALK may suppress p53 activity through miR-135b-PPP2R5C axis, and upregulation of MDM2 and JNK activities reported previously 14 ( Figure 2h ).
Our findings reinforce the possibility of inference of miRNA regulation underlying the mRNA profiles from numerous gene expression data sets in publicly accessible repositories, even if these studies included one-sided mRNA profiles and did not design miRNA profiling. The results in Figures 2b and c; and Supplementary Figure S2 suggest that a subset of miRNA target genes can represent the biological activity of corresponding miRNAs. Png et al. 15 recently showed similar approach, in which eight miR-126 target genes reflect the metastasissuppressor activity of miR-126 and strongly correlate with metastatic relapse in human breast cancer. GFA may be useful for the identification of such representative miRNA target genes. The present study suggests that combinational investigation of gene expression profiling and computational miRNA activity predictions may yield a wide platform for assessment of miRNA involvement in various disease processes, together with miRNA profiling.
Letters to the Editor
